Moderna 2022 Priorities and Capital Allocation
A fourth dose of Moderna's COVID-19 Vaccine increased vaccine effectiveness
against infection, symptomatic infection and severe outcomes in high-risk population
.
.
An Ontario study observed waning
of a third dose for individuals who
received a booster ≥84 days ago
A 100 μg dose of mRNA-1273 is
recommended for LTC residents in
Ontario for boosters; Almost all LTC
residents (97%) who received a
fourth dose received mRNA-1273
In 56,806 long-term care residents
that were tested, a fourth dose
increased VE against all three
outcomes compared to residents
who received a third dose ≥84
days ago
Slide 11
Marginal effectiveness (%)
Effectiveness of a fourth dose of mRNA COVID-19
vaccine against Omicron outcomes
A. Infection
100-
80-
60-
40.
20-
0
T
<7 days ≥7 days
Days since fourth dose
Marginal effectiveness (%)
B. Symptomatic infection
100-
80-
60-
40-
20-
0
<7 days 27 days
Days since fourth dose
Grewal, Ramandip et al., https://www.medrxiv.org/content/10.1101/2022.04.15.22273846v1
Marginal effectiveness (%)
C. Severe outcomes
100-
80-
60-
40-
т
20-
0
<7 days
≥7 days
Days since fourth dose
modernaView entire presentation